loader

BioVaxys Technology Corp.

CNSX:BIOV
BVAXF
1 min read

BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M

BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES

BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS

BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS

BIOVAXYS ANNOUNCES LIFE OFFERING

BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement

BIOVAXYS ANNOUNCES CLOSING OF UNSECURED CONVERTIBLE DEBENTURE OFFERING

CSE Bulletin: Consolidation - BioVaxys Technology Corp.

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.

Latest News

More News

Latest News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES